Retargeting oncolytic adenoviruses from their systemic preeminent liver tropism to disseminated tumor foci would highly improve the efficacy of these agents at eradicating tumors. We have replaced the KKTK fiber shaft heparan sulfate glycosaminoglycan-binding domain with an RGDK motif in order to achieve simultaneously liver detargeting and tumor targeting. When inserted into a wild-type backbone, this mutation palliated liver transaminase elevation and hematological alterations in mice. Importantly, when tested in a backbone that redirects E1A transcription towards pRB pathway deregulation, RGD at this novel shaft location also improved significantly systemic antitumor therapy compared with the broadly used RGD location at the HI-loop of the fiber knob domain. Gene Therapy (2012) Keywords: oncolytic adenovirus; fiber shaft; HSG-binding domain; RGD motif; antitumor efficacy INTRODUCTION Oncolytic adenoviruses are promising therapies for cancer treatment owing to their ability to self-amplify at the tumor site. However, systemic delivery of Ad5 results in a rapid clearance from the bloodstream and the sequestration of the virus in the liver, which causes toxicity and a drop in virus bioavailability. 1 As the success of adenoviral therapy depends on the ability of adenoviruses to reach disseminated cancer cells, this liver tropism limits the efficacy of the therapy upon systemic administration. To overcome this limitation, capsid retargeting mutations are under study.To retarget Ad5 to tumor sites, it is necessary to abrogate liver transduction (liver detargeting) and to expose new ligands specific for tumor cells on capsid proteins (tumor targeting). To achieve liver detargeting, several mutations on capsid proteins, such as the double ablation of CAR and integrin binding, have failed to reduce hepatocyte transduction in vivo owing to the role of blood factors in adenovirus liver transduction. 2,3 Recently, ablation of Factor X binding by the hexon has resulted in successful liver-detargeting, 4,5 although this might be at the expense of lower tumor targeting. 6 Alternatively, the mutation of the heparan sulfate glycosaminoglycan (HSG) putative-binding site KKTK of the Ad5 fiber shaft domain detargets liver transduction, probably because of affectation of the bending or structure of the fiber. 2,7,8 On the other hand, the HI-loop of the fiber knob domain has been used to accommodate a broad range of tumor-selective peptides for tumor targeting 9-11 Among all peptides incorporated into the HI loop, the CDCRGDCFC motif (known as RGD-4C) has been broadly used and confers on Ad5 a CAR-independent entry mechanism by using aV-b3 and aV-b5 integrins as primary receptors. 12,13 As integrins are a large family of adhesive receptors involved in the spread and adhesion